

# Theranostic Cathepsin Activity-Based Probe for Noninvasive Intervention in Cardiovascular Diseases


Tommy Weiss-Sadan<sup>1,#</sup>, Yael Ben-Nun<sup>1,#</sup>, David Maimoun<sup>2</sup>, Emmanuelle Merquiol<sup>1</sup>, Ihab Abd-Elrahman<sup>1</sup>, Israel Gotsman<sup>2\*</sup>, Galia Blum<sup>1\*</sup>

<sup>1</sup>*Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel, 9112001.* <sup>2</sup>*Heart institute, Hadassah, University Hospital, Jerusalem, Israel 91120.*

<sup>#</sup>These authors contributed equally to this work.


\*Corresponding authors: Galia Blum<sup>1</sup>, [galiabl@ekmd.huji.ac.il](mailto:galiabl@ekmd.huji.ac.il) and Israel Gotsman<sup>2</sup>, [igotsman@bezeqint.net](mailto:igotsman@bezeqint.net)

**Running title:** Theranostic application for qPD-ABP in cardiovascular diseases



**Supplementary Figure 1. Mice weight gain after twelve weeks on a high-fat diet compared to normal chow.** Mice were fed high-fat diet (n=7) or normal chow (n=5) for twelve weeks, and their weight was recorded on every other week. Data present the mean  $\pm$  SEM. Student's t-test used to evaluate the statistical difference between groups and adjusted for multiple hypothesis correction with the False Discovery Rate (FDR). *P* values below 0.05 were considered statistically different. \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

■ Dark ■ PDT



**Supplementary Figure 2. Lipid profiles of mice on a high-fat diet.** Serum lipid profile of mice fed high-fat diet for twelve weeks. Metabolic measurements were performed in a double-blind manner by external clinical laboratory service. Data summarized in bar graphs present the mean  $\pm$  SEM of four to five mice per group. The statistical difference for each parameter was determined by a student's t-test and corrected for multiple hypotheses using the false discovery rate (FDR). Therefore, the *P* values represent the adjusted values after FDR correction. There was no significant difference in the metabolic parameters between the PDT and Dark treatment. *P* values are indicated in the figure.

**Supplementary method. Synthesis of photosensitizer quenched activity-based theranostic agent** Schematic description of YBN14 synthesis and essential elements as previously described <sup>11</sup>. YBN14 is designed according to the principles of GB137, a quenched activity-based probe presented by Blum G and colleagues <sup>12</sup>. The photosensitizer (b-Chlo, Pink) and quencher ( QC-1, blue) pair are highlighted. Fmoc, 9-fluorenylmethylcarbonyl; DMF, dimethylformamide; HOBt, 1-hydroxybenzotriazole; DIEA, diisopropylethylamine; PyBOP, (benzotriazole-1-yl-oxy)tris(pyrrolidino)phosphonium hexafluorophosphate; DCM, dichloromethane; Boc, t-butyloxycarbonyl; b-Chlo, Bacteriochlorin (Pink); TFA, trifluoroacetic acid; DMSO, dimethyl sulfoxide.